Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Progenics Pharmaceuticals (PGNX)

Progenics Pharmaceuticals (PGNX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 355,048
  • Shares Outstanding, K 86,597
  • Annual Sales, $ 34,990 K
  • Annual Income, $ -68,550 K
  • 60-Month Beta 1.89
  • Price/Sales 11.20
  • Price/Cash Flow N/A
  • Price/Book 11.60
Trade PGNX with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.77
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 08/14/20
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/20
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year -0.23
  • Growth Rate Est. (year over year) +434,447.83%

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.72 +10.22%
on 05/20/20
4.83 -15.12%
on 06/08/20
+0.47 (+12.95%)
since 05/19/20
3-Month
2.05 +100.00%
on 03/20/20
4.83 -15.12%
on 06/08/20
+1.99 (+94.31%)
since 03/19/20
52-Week
1.89 +116.93%
on 03/19/20
6.37 -35.64%
on 12/23/19
-0.78 (-15.98%)
since 06/19/19

Most Recent Stories

More News
Chronic Idiopathic Constipation (CIC) Drugs Market Research Report with Size, Share, Value, CAGR, Outlook, Analysis, Latest Updates, Data, and News 2020-2025

This report elaborates the market size, market characteristics, and market growth of the Chronic Idiopathic Constipation (CIC) Drugs industry, and breaks down according to the type, application, and consumption...

LLY : 247.23 (+1.53%)
GSK : 40.24 (+0.25%)
IRWD : 13.30 (+0.23%)
MRK : 76.26 (-0.79%)
PGNX : 4.10 (-9.39%)
SCMP : 18.05 (+0.28%)
VRX.TO : 30.80 (-3.33%)
Worldwide Neuroendocrine Tumor Treatment Industry to 2029 - Players Include Advanced Accelerator Applications, Novartis & Progenics Pharmaceuticals Among Others - ResearchAndMarkets.com

The "Neuroendocrine Tumor Treatment Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2019 to 2029" report has been added...

PGNX : 4.10 (-9.39%)
Global Antibody Drug Conjugates Market Size Will Reach USD 4,670 Million By 2026: Facts & Factors

Facts and Factors have published a new research report titled "Antibody Drug Conjugates Market by Drugs (Adcetris and Kadcyla), Mechanism of Action (CD30 Antibodies and HER2 Antibodies), Application (Breast...

IMGN : 5.76 (+2.67%)
IMMU : 87.86 (+0.05%)
PFE : 43.95 (+2.66%)
PGNX : 4.10 (-9.39%)
SGEN : 153.45 (+0.04%)
Opioid Induced Side Effects Treatment Market Global Trends, Market Share, Industry Size, Growth, Opportunities and Market Forecast 2020 to 2027

The report for Opioid Induced Side Effects Treatment offers an assiduous analysis of contemporary market trends, driving factors, consumer behavior, key player strategies, product usage and brand positioning....

PGNX : 4.10 (-9.39%)
TBPH : 13.62 (+4.93%)
VRX.TO : 30.80 (-3.33%)
PyL(TM) (18F-DCFPyL), Lantheus' PSMA-Targeted Prostate Cancer Imaging Agent, to be Used in POINT Biopharma's PSMA-Targeted Radioligand Therapeutic Phase 3 Trial in Patients with Metastatic Castration Resistant Prostate Cancer

Lantheus Holdings, Inc. (NASDAQ: LNTH) (Lantheus), the parent company of Lantheus Medical Imaging, Inc. and Progenics Pharmaceuticals, Inc., a global leader in the development, manufacture and commercialization...

PGNX : 4.10 (-9.39%)
LNTH : 26.84 (+2.56%)
Lantheus Holdings Announces FDA Clearance for AI-Enabled Automated Bone Scan Index (aBSI) in Prostate Cancer on GE Healthcare's Xeleris Platform

Lantheus Holdings, Inc. (the "Company") (NASDAQ: LNTH), the parent company of Lantheus Medical Imaging, Inc., Progenics Pharmaceuticals, Inc., and EXINI Diagnostics AB, and a global leader in the development,...

PGNX : 4.10 (-9.39%)
LNTH : 26.84 (+2.56%)
GE : 100.95 (-2.56%)
SOFIE Signs Commercial Supply Agreement with Lantheus Holdings, Inc. to Manufacture PyL™ (18F-DCFPYL), a PSMA-targeted Prostate Cancer Imaging Agent

, /PRNewswire/ -- SOFIE, an established Radiopharmaceutical Contract Manufacturing Organization and GMP radiopharmacy network, has signed a commercial supply agreement with Lantheus Holdings, Inc. (the...

PGNX : 4.10 (-9.39%)
CORRECTION: TIME CHANGE - Lantheus Holdings to Present at November 2020 Investor Conferences

Lantheus Holdings, Inc. (the "Company") (NASDAQ: LNTH), the parent company of Lantheus Medical Imaging, Inc., Progenics Pharmaceuticals, Inc. and EXINI Diagnostics AB, and a global leader in the development,...

PGNX : 4.10 (-9.39%)
LNTH : 26.84 (+2.56%)
Lantheus Holdings to Present at November 2020 Investor Conferences

Lantheus Holdings, Inc. (the "Company") (NASDAQ: LNTH), the parent company of Lantheus Medical Imaging, Inc., Progenics Pharmaceuticals, Inc. and EXINI Diagnostics AB, and a global leader in the development,...

PGNX : 4.10 (-9.39%)
LNTH : 26.84 (+2.56%)
Lantheus Holdings Announces Presentations at the 33rd Annual European Association of Nuclear Medicine (EANM) Virtual Congress

Lantheus Holdings, Inc. (the "Company") (NASDAQ: LNTH), the parent company of Lantheus Medical Imaging, Inc., Progenics Pharmaceuticals, Inc., and EXINI Diagnostics AB, and a global leader in the development,...

PGNX : 4.10 (-9.39%)
LNTH : 26.84 (+2.56%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Sell with a Weakest short term outlook on maintaining the current direction.

See More Share

Business Summary

Progenics Pharmaceuticals, Inc. is developing innovative medicines for oncology, with a pipeline that includes several product candidates in later-stage clinical development. Progenics' first-in-class PSMA-targeted technology platform for prostate cancer includes an antibody drug conjugate therapeutic...

See More

Key Turning Points

3rd Resistance Point N/A
2nd Resistance Point 5.13
1st Resistance Point 4.61
Last Price 4.10
1st Support Level 3.76
2nd Support Level 3.43
3rd Support Level N/A

See More

52-Week High 6.37
Fibonacci 61.8% 4.66
Fibonacci 50% 4.13
Last Price 4.10
Fibonacci 38.2% 3.60
52-Week Low 1.89

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar